Bertha Castillio

Bertha Castillio

Auto-generated profile, based on publicly available information

Bertha Castillio

Department of Bioengineering, Rice University, Houston, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Purpose: IL2 immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical utility is limited due to pharmacokinetic challenges as well as vascular leak syndrome and other life-threatening toxicities experienced by patients. We developed a safe and clinically translatable localized IL2 delivery system to boost the potency of therapy while minimizing systemic cytokine exposure. Experimental Design: We evaluated the therapeutic efficacy of IL2 cytokine factories in a mouse model of malignant mesothelioma. Changes in immune populations were analyzed using time-of-flight mass cytometry (CyTOF), and the safety and translatability of the platform were evaluated using complete blood counts and serum chemistry analysis. Results: IL2 cytokine factories enabled 150× higher IL2 concentrations in the local compartment with limited leakage into the systemic circulation. AB1 tumor burden was reduced by 80% after 1 week of monotherapy treatment, and 7 of 7 of animals exhibited tumor eradication without recurrence when IL2 cytokine factories were combined with anti–programmed cell death protein 1 (aPD1). Furthermore, CyTOF analysis showed an increase in CD69+CD44+ and CD69−CD44+CD62L− T cells, reduction of CD86−PD-L1− M2-like macrophages, and a corresponding increase in CD86+PD-L1+ M1-like macrophages and MHC-II+ dendritic cells after treatment. Finally, blood chemistry ranges in rodents demonstrated the safety of cytokine factory treatment and reinforced its potential for clinical use. Conclusions: IL2 cytokine factories led to the eradication of aggressive mouse malignant mesothelioma tumors and protection from tumor recurrence, and increased the therapeutic efficacy of aPD1 checkpoint therapy. This study provides support for the clinical evaluation of this IL2-based delivery system. See related commentary by Palanki et al., p. 5010

1 April 2023
Verified
Other
Open access
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

1 April 2023
Verified
Other
Open access
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

1 April 2023
Verified
Other
Open access
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

1 April 2023
Verified
Other
Open access
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Purpose:IL2 immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical utility is limited due to pharmacokinetic challenges as well as vascular leak syndrome and other life-threatening toxicities experienced by patients. We developed a safe and clinically translatable localized IL2 delivery system to boost the potency of therapy while minimizing systemic cytokine exposure.Experimental Design:We evaluated the therapeutic efficacy of IL2 cytokine factories in a mouse model of malignant mesothelioma. Changes in immune populations were analyzed using time-of-flight mass cytometry (CyTOF), and the safety and translatability of the platform were evaluated using complete blood counts and serum chemistry analysis.Results:IL2 cytokine factories enabled 150× higher IL2 concentrations in the local compartment with limited leakage into the systemic circulation. AB1 tumor burden was reduced by 80% after 1 week of monotherapy treatment, and 7 of 7 of animals exhibited tumor eradication without recurrence when IL2 cytokine factories were combined with anti–programmed cell death protein 1 (aPD1). Furthermore, CyTOF analysis showed an increase in CD69+CD44+ and CD69−CD44+CD62L− T cells, reduction of CD86−PD-L1− M2-like macrophages, and a corresponding increase in CD86+PD-L1+ M1-like macrophages and MHC-II+ dendritic cells after treatment. Finally, blood chemistry ranges in rodents demonstrated the safety of cytokine factory treatment and reinforced its potential for clinical use.Conclusions:IL2 cytokine factories led to the eradication of aggressive mouse malignant mesothelioma tumors and protection from tumor recurrence, and increased the therapeutic efficacy of aPD1 checkpoint therapy. This study provides support for the clinical evaluation of this IL2-based delivery system.See related commentary by Palanki et al., p. 5010

1 April 2023
Verified
Other
Open access
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Supplementary Figure from Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors